AbbVie : J.P. Morgan Healthcare Conference Presentation 985.1 KB

J.P. Morgan Healthcare Conference

Richard Gonzalez

Chairman and Chief Executive Officer

January 12, 2021

Forward-Looking Statements and Non-GAAP Financial information

Some statements in this presentation are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward- looking statements. Such risks and uncertainties include, but are not limited to, the failure to realize the expected benefits of AbbVie's acquisition of Allergan or to promptly and effectively integrate Allergan's business, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2019 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

This presentation contains GAAP and certain non-GAAP financial measures. Non-GAAP financial measures are adjusted for certain non-cash items and for factors that are unusual or unpredictable, and exclude those costs, expenses and other specified items presented in AbbVie's reconciliation tables. AbbVie's management believes non-GAAP financial measures provide useful information to investors regarding AbbVie's results of operations and assist management, analysts and investors in evaluating the performance of the business. Non-GAAP financial measures should be considered in addition to, and not as a substitute for, measures of financial performance prepared in accordance with GAAP. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures are available in the appendix to this presentation and on the company's website at www.abbvieinvestor.com.

Today's discussions and presentation are intended for the investor community only; materials are not intended to promote the products referenced herein or otherwise influence healthcare prescribing decisions.

Not for promotional use	J.P. Morgan Healthcare Conference | January 12, 2021	2

AbbVie is a Diversified Biopharmaceutical Company

Well-Positioned for Sustainable Growth

Strong Leadership Positions in Attractive Growth Markets

Immunology		Hematologic Oncology

Neuroscience		Allergan Aesthetics

Not for promotional use	J.P. Morgan Healthcare Conference | January 12, 2021	3

Broad Portfolio and Pipeline of Attractive, Durable Growth Assets

Large, Diverse On-Market Portfolio and Robust Pipeline of

Novel Therapies Will Drive Return to Revenue Growth in 2024

• Continued strong top-line growth expected leading up to U.S. Humira LOE event in 2023
• Expect total company sales to decline in 2023 following U.S. Humira LOE
• Quickly return to growth following U.S. Humira LOE, with modest top-line growth expected in 2024
• Expect rapid return to strong top-line growth in 2025, with high-single digit CAGR through remainder of decade

Not for promotional use	J.P. Morgan Healthcare Conference | January 12, 2021	4